Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis
- 12 January 2026
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 40 (3) , 502-510
Abstract
The prevailing fixed-hierarchy approach to donor selection for allogeneic hematopoietic cell transplantation (HCT) fails to capture critical interactions between donor age and type. We addressed this by analyzing 1713 adult recipients of matched related (MRD), matched unrelated (MUD), or haploidentical donors, receiving post-transplantation cyclophosphamide, using both regularized-Cox and XGBoost machine learning models. Our analysis revealed that the overall, independent association of donor age with survival was modest; however, its importance became pivotal within specific, context-dependent trade-offs. For example, while age-matched MRD and MUD were equivalent, a younger MUD was superior to an older MRD for elderly recipients. The survival advantage of MUD over haploidentical donors was consistent and magnified with increasing recipient age. We identified a non-linear relationship between baseline risk and the benefit of a matched versus a haploidentical donor; with the gain being maximal for intermediate-risk patients but attenuated in the highest-risk stratum. Our framework quantifies the gap that persists even between HLA-favorable haploidentical donors and matched donors. These findings provide a quantitative framework –the principles of which we have made explorable via an interactive web application –for a personalized, risk-adapted approach to donor selection. The clinical utility of this model must be confirmed in future validation studies.Keywords
This publication has 33 references indexed in Scilit:
- Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid LeukemiaTransplantation and Cellular Therapy, 2023
- HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor ageBlood Advances, 2022
- Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideTransplantation and Cellular Therapy, 2022
- HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamideBlood, 2022
- HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisBlood, 2021
- Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamideBlood Advances, 2021
- Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamideBlood Advances, 2018
- Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantationAmerican Journal of Hematology, 2017
- The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancyBlood, 2016
- Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective studyThe Lancet Oncology, 2012